Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Taspoglutide
Другие языки:

Taspoglutide

Подписчиков: 0, рейтинг: 0

Taspoglutide
Clinical data
Routes of
administration
subcutaneous
ATC code
  • none
Pharmacokinetic data
Bioavailability N/A
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C152H232N40O45
Molar mass 3339.763 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Taspoglutide is a former experimental drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), that was under investigation for treatment of type 2 diabetes and being codeveloped by Ipsen and Roche.

Initially, phase II trials reported it was effective and well tolerated.

Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009. Preliminary results in early 2010 were favourable. (At least one of the eight planned phase III trials had not started recruiting by end 2009.)

In September 2010 Roche halted Phase III clinical trials due to instances of serious hypersensitivity reactions and gastrointestinal side effects.

As of May 2022 no new trials have been registered since 2010.

Chemistry

Taspoglutide is the peptide with the sequence H2N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2.

In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.

See also



Новое сообщение